Compound 21is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke

Journal of Hypertension

Volumn 33, Issue 1, 2015, Pages 170-180

  Alhusban, Ahmed ^b   Fouda, Abdelrahman Y ^a   Pillai, Bindu ^a   Ishrat, Tauheed ^a   Soliman, Sahar ^a   Fagan, Susan C ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Angiotensin II type 2 receptor; Blood pressure; Compound 21; Stroke

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOGENIC FACTOR; ANGIOTENSIN 2 RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANGIOGENESIS; ANIMAL; BLOOD PRESSURE; BRAIN; BRAIN ISCHEMIA; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; MALE; METABOLISM; MIDDLE CEREBRAL ARTERY; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; RAT; STROKE; TIME; TREATMENT OUTCOME; WISTAR RAT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BLOOD PRESSURE; BRAIN; BRAIN ISCHEMIA; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; IMIDAZOLES; MALE; MIDDLE CEREBRAL ARTERY; NEOVASCULARIZATION, PHYSIOLOGIC; PYRIDINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 2; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84916641916     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000364     Document Type: Article

References (62)

1. Stroke information. 2013 December 11, 2013. http://www.cdc.gov/stroke/. [cited 23 December 2013].
2. Guimond MO, Gallo-Payet N. The angiotensin II type 2 receptor in brain functions: An update. Int J Hypertens 2012; 2012: 351758.
3. Gallo-Payet N, Guimond M-O, Bilodeau L, Wallinder C, Alterman M, Hallberg A. Angiotensin II, a neuropeptide at the frontier between endocrinology and neuroscience: Is there a link between the angiotensin II type 2 receptor (AT2R) and Alzheimer's disease Front Endocrinol 2011; 2: 17.
4. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002; 33: 2297-2303.
5. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, et al. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 2004; 24: 467-474.
6. Groth W, Blume A, Gohlke P, Unger T, Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 2003; 21: 2175-2182.
7. Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, et al. Hypertension after experimental cerebral ischemia: Candesartan provides neurovascular protection. J Hypertens 2006; 24: 535-539.
8. Kozak A, Ergul A, El-Remessy AB, Johnson MH, Machado LS, Elewa HF, et al. Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke 2009; 40: 1870-1876.
9. Sandset EC, Bath PM, Boysen G, Jatuzis D, Korv J, Luders S, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): A randomised, placebo-controlled, double-blind trial. Lancet 2011; 377: 741-750.
10. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110: 843-848.
11. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617-619.
12. Lu Q, Zhu YZ, Wong PT. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 2005; 16: 1963-1967.
13. Alhusban A, Kozak A, Ergul A, Fagan SC. AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. J Pharmacol Exp Therapeut 2013; 344: 348-359.
14. McCarthy CA, Vinh A, Callaway JK, Widdop RE. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke 2009; 40: 1482-1489.
15. McCarthy CA, Vinh A, Broughton BR, Sobey CG, Callaway JK, Widdop RE. Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious rats. Hypertension 2012; 60: 1531-1537.
16. Dorrance AM. Angiotensin II type 2 receptor agonists as therapies for ischemic stroke. Hypertension 2012; 60: 1391-1392.
17. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, et al. Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-Angiotensin system in myocardial infarction? Circulation 2008; 118: 2523-2532.
18. Erin Bruce VS, Joseph Francis U, Muscha S, Thomas U, Colin S, Mohan K, et al. Stimulation of angiotensin type 2 receptor as a potential therapy for pulmonary hypertension. Los Angeles: Scientific Sessions; 2012.
19. Joseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodriguez V, Desland F, et al. The angiotensin type 2 receptor agonist compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology 2014; 81c: 134-141.
20. Min LJ, Mogi M, Tsukuda K, Jing F, Ohshima K, Nakaoka H, et al. Direct stimulation of angiotensin ii type 2 receptor initiated after stroke ameliorates ischemic brain damage. Am J Hypertens 2014; 27: 1036-1044.
21. Guan W, Somanath PR, Kozak A, Goc A, El-Remessy AB, Ergul A, et al. Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. PloS One 2011; 6: E24551.
22. Macova M, Pavel J, Saavedra JM. A peripherally administered, centrally acting angiotensin II AT2 antagonist selectively increases brain AT1 receptors and decreases brain tyrosine hydroxylase transcription, pituitary vasopressin and ACTH. Brain Res 2009; 1250: 130-140.
23. Fagan SC, Nagaraja TN, Fenstermacher JD, Zheng J, Johnson M, Knight RA. Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a nonembolic stroke model. Neurol Res 2003; 25: 377-382.
24. FoudaA, KozakA, AlhusbanA, Switzer J, FaganS.Anti-inflammatoryIL-10 is upregulated in both hemispheres after experimental ischemic stroke: Hypertension blunts the response. Exp Transl Stroke Med 2013; 5: 12.
25. Ishrat T, Pillai B, Ergul A, Hafez S, Fagan SC. Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke. Neurochem Res 2013; 38: 2668-2677.
26. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003; 162: 1995-2004.
27. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurologic examination. Stroke 1986; 17: 472-476.
28. Watanabe T, Okuda Y, Nonoguchi N, Zhao MZ, Kajimoto Y, Furutama D, et al. Postischemic intraventricular administration of FGF-2 expressing adenoviral vectors improves neurologic outcome and reduces infarct volume after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2004; 24: 1205-1213.
29. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001; 32: 1005-1011.
30. Kagiyama T, Kagiyama S, Phillips MI. Expression of angiotensin type 1 and 2 receptors in brain after transient middle cerebral artery occlusion in rats. Regul Pept 2003; 110: 241-247.
31. Atochin DN, Wang A, Liu VW, Critchlow JD, Dantas AP, Looft-Wilson R, et al. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Investig 2007; 117: 1961-1967.
32. Dhande I, Ali Q, Hussain T. Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: Role in renoprotection in obese rats. Hypertension 2013; 61: 1218-1226.
33. Cui X, Chopp M, Zacharek A, Ning R, Ding X, Roberts C, et al. Endothelial nitric oxide synthase regulates white matter changes via the BDNF/TrkB pathway after stroke in mice. PloS One 2013; 8: E80358.
34. Chen J, Zacharek A, Zhang C, Jiang H, Li Y, Roberts C, et al. Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J Neurosci 2005; 25: 2366-2375.
35. Terpolilli NA, Moskowitz MA, Plesnila N. Nitric oxide: Considerations for the treatment of ischemic stroke. J Cereb Blood Flow Metab 2012; 32: 1332-1346.
36. Saavedra JM. Brain angiotensin II: New developments, unanswered questions and therapeutic opportunities. Cell Molec Neurobiol 2005; 25: 485-512.
37. Zhu YZ, Chimon GN, Zhu YC, Lu Q, Li B, Hu HZ, et al. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport 2000; 11: 1191-1194.
38. Namsolleck P, Boato F, Schwengel K, Paulis L, Matho KS, Geurts N, et al. AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol Dis 2013; 51: 177-191.
39. Zhang Y, Pardridge WM. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res 2006; 1111: 227-229.
40. Schabitz WR, Berger C, Kollmar R, Seitz M, Tanay E, Kiessling M, et al. Effect of brain-derived neurotrophic factor treatment and forced arm use on functional motor recovery after small cortical ischemia. Stroke 2004; 35: 992-997.
41. Schabitz WR, Steigleder T, Cooper-Kuhn CM, Schwab S, Sommer C, Schneider A, et al. Intravenous brain-derived neurotrophic factor enhances poststroke sensorimotor recovery and stimulates neurogenesis. Stroke 2007; 38: 2165-2172.
42. Zhang Y, Pardridge WM. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 2001; 32: 1378-1384.
43. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. Some remarks on the growth-rate and angiogenesis of microvessels in ischemic stroke. Morphometric and immunocytochemical studies. Patologia Polska 1993; 44: 203-209.
44. Ergul A, Alhusban A, Fagan SC. Angiogenesis: A harmonized target for recovery after stroke. Stroke 2012; 43: 2270-2274.
45. Curato C, Slavic S, Dong J, Skorska A, Altarche-Xifro W, Miteva K, et al. Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury. J Immunol (Baltimore Md: 1950) 2010; 185: 6286-6293.
46. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 1998; 251: 189-192.
47. Grilli M, Barbieri I, Basudev H, Brusa R, Casati C, Lozza G, et al. Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. Eur J Neurosci 2000; 12: 2265-2272.
48. Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-Arginine. J Cereb Blood Flow Metab 1996; 16: 981-987.
49. Zhang ZG, Reif D, Macdonald J, Tang WX, Kamp DK, Gentile RJ, et al. ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1996; 16: 599-604.
50. Hara H, Huang PL, Panahian N, Fishman MC, Moskowitz MA. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab 1996; 16: 605-611.
51. Iadecola C, Zhang F, Xu X. Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol 1995; 268 ((1 Pt 2)): R286-R292.
52. Iadecola C, Zhang F, Casey R, Nagayama M, Ross ME. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997; 17: 9157-9164.
53. Gursoy-Ozdemir Y, Can A, Dalkara T. Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 2004; 35: 1449-1453.
54. Eliasson MJ, Huang Z, Ferrante RJ, Sasamata M, Molliver ME, Snyder SH, et al. Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage. J Neurosci 1999; 19: 5910-5918.
55. Forster C, Clark HB, Ross ME, Iadecola C. Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol 1999; 97: 215-220.
56. Xu J, He L, Ahmed SH, Chen SW, Goldberg MP, Beckman JS, et al. Oxygen-glucose deprivation induces inducible nitric oxide synthase and nitrotyrosine expression in cerebral endothelial cells. Stroke 2000; 31: 1744-1751.
57. Tajes M, Ill-Raga G, Palomer E, Ramos-Fernandez E, Guix FX, Bosch-Morato M, et al. Nitro-oxidative stress after neuronal ischemia induces protein nitrotyrosination and cell death. Oxid Med Cell Longev 2013; 2013: 826143.
58. Verdonk K, Durik M, Abd-Alla N, Batenburg WW, van den Bogaerdt AJ, van Veghel R, et al. Compound 21 induces vasorelaxation via an endothelium-And angiotensin II type 2 receptor-independent mechanism. Hypertension 2012; 60: 722-729.
59. McCarthy CA, Vinh A, Miller AA, Hallberg A, Alterman M, Callaway JK, et al. Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. PloS One 2014; 9: E95762.
60. Zhang Y, Gao Z, Wang D, Zhang T, Sun B, Mu L, et al. Accumulation of natural killer cells in ischemic brain tissues and the chemotactic effect of IP-10. J Neuroinflamm 2014; 11: 79.
61. Gan Y, Liu Q, Wu W, Yin JX, Bai XF, Shen R, et al. Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci U S A 2014; 111: 2704-2709.
62. Kraus L, Trautewig B, Klempnauer J, Lieke T. Naive rat NK cells control the onset of T cell response. PloS One 2012; 7: E47074.